Understanding Disease-Drug Interactions in Cancer Patients: Implications for Dosing Within the Therapeutic Window
D E Coutant1, P Kulanthaivel1, P K Turner2
1Department of Drug Disposition, Eli Lilly and Company, Indianapolis, Indiana, USA.
Abstract:
The human inflammatory response can result in the alteration of drug clearance through effects on metabolizing enzymes or transporters. In this article we briefly review the theory of how cancer can lead to indirect changes in drug metabolism, review acute phase proteins and cytokines as markers of changes in cytochrome P450 (CYP) activity in cancer patients, and provide clinical case examples of how the inflammation in advanced cancer patients can lead to altered CYP-mediated drug clearance.
More Related Videos
07:40A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions
Published on: May 27, 2021
08:57Sample Extraction and Simultaneous Chromatographic Quantitation of Doxorubicin and Mitomycin C Following Drug Combination Delivery in Nanoparticles to Tumor-bearing Mice
Published on: October 5, 2017
Related Concept Videos
Pharmacokinetics: Drug–Drug Interactions
Drug toxicity: Drug–Drug Interaction
Pharmacokinetics: Drug–Food and Drug–Viral Interactions
Therapeutic Drug Monitoring: Affecting Factors
Drug Dosing: Geriatric Patients
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
